News
Novartis Multiple Sclerosis Drug Kesimpta Shows Substantial Benefit Of Up To 6 Years
17 Apr 24
Biotech, Large Cap, News, Health Care, General
Novartis Announced Earlier, Continuous Kesimpta Treatment For Up To Six Years Showed Sustained Efficacy In Recently Diagnosed (≤3 Years) Treatment-naïve People Living With Relapsing Multiple Sclerosis In Analysis Of Alithios Open-label Extension Study
17 Apr 24
News
Avalo Therapeutics' Newly Acquired Ex-Eli Lilly Drug Could Stand Out In Competitive Hidradenitis Suppurativa Market, Analyst Upgrades
16 Apr 24
Analyst Color, Biotech, Equities, News, Upgrades, Health Care, Price Target, Analyst Ratings, Movers, Trading Ideas, General
MorphoSys AG Form SC TO-T/Amended Shows Novartis BidCo AG Bought 2,023,370 Shares Of Common Stock Or About A 5.36% Stake; Highest Price Paid Was €67.95 Per Share
15 Apr 24
M&A
Novartis Fabhalta Data Show Clinically Meaningful And Statistically Significant Proteinuria Reduction Of 38.3% Versus Placebo For Patients With IgA Nephropathy
15 Apr 24
Biotech, News, General
Vertex's Alpine Acquisition: Unpacking Analyst Predictions on Povetacicept's Potential Impact
11 Apr 24
Analyst Color, Biotech, Equities, Large Cap, M&A, News, Upgrades, Health Care, Price Target, Analyst Ratings, Trading Ideas, General
Looking At Novartis's Recent Unusual Options Activity
11 Apr 24
Options, Markets
Arvinas Enters Exclusive Strategic License Agreement With Novartis; Arvinas To Receive $150M Upfront Payment & Up To $1.01B In Milestones
11 Apr 24
News, Contracts
Novartis Tender Offer For Morphosys Commences @€68.00/Share
11 Apr 24
M&A, News
Why Is Kidney Disease-Focused Alpine Immune Sciences Stock Trading Higher On Wednesday?
10 Apr 24
Biotech, M&A, News, Health Care, Rumors, Top Stories, Movers, General
Enliven Therapeutics Well-Positioned, With Conservative Trading Levels-Analyst Says
9 Apr 24
Analyst Color, Biotech, Equities, News, Health Care, Price Target, Initiation, Analyst Ratings, Trading Ideas, General
Novartis To Axe 680 Development Jobs Amid Global Reshuffle: Report
9 Apr 24
Equities, News, Health Care, Markets, Media, General
Johnson & Johnson's Carvykti Stands Ahead Of Bristol Myers' Rival Blood Cancer Therapy With FDA Approval For Wider Population
8 Apr 24
Analyst Color, Biotech, Equities, Large Cap, News, Health Care, Price Target, Reiteration, FDA, Analyst Ratings, Trading Ideas, General
Novartis Announced Saturday, Data Show Early Addition Of Twice-yearly Leqvio Following Maximally Tolerated Statin Therapy Significantly Reduces LDL-C In ASCVD Patients In Real-world Setting
7 Apr 24
News
Why Is Novartis Stock Trading Higher On Thursday?
4 Apr 24
Biotech, Equities, Large Cap, News, Health Care, Movers, General
Novartis Earlier Said It Plans To File For Pluvicto Pre-Taxane Label Expansion In H2 2024 Based On Data From Phase III PSMAfore Study
4 Apr 24
Biotech, News, General
Novartis Pharmaceuticals Canada Announced Health Canada Grants Approval Of The Eye-tracking Neurological Assessment For Multiple Sclerosis For Use In Tracking Disease Progression In People Living With MS
25 Mar 24
News, FDA
Magnificent 7 Stocks Become The Star Attractions For Norway's Sovereign Wealth Fund
25 Mar 24
Equities, Government, Large Cap, News, Bonds, Management, Top Stories, Economics, Markets, Tech, General, Real Estate
Ozempic Users Speak Out Over Side Effects, Lawsuits Against Novo Nordisk And Eli Lilly Surge
22 Mar 24
Biotech, Large Cap, News, Health Care, Legal, General
On 21 March 2024, The CHMP Adopted A Positive Opinion, Recommending The Granting Of A Marketing Authorization For Novartis' Fabhalta1, Intended For The Treatment Of Paroxysmal Nocturnal Haemoglobinuria
22 Mar 24
News, FDA
Press releases
New Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN)
15 Apr 24
Press Releases
Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer
11 Apr 24
News, Contracts, Press Releases
New Novartis data show early addition of twice-yearly* Leqvio® (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world setting
6 Apr 24
Press Releases
Biotech's Role in Addressing the Pancreatic Cancer Emergency
14 Mar 24
Small Cap, Opinion, Press Releases